Adma Biologics Inc
Q1 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +6.73%.
Did ADMA Beat Earnings? Q1 2025 Results
ADMA Biologics delivered a quarter of sharp top-line growth but came in just shy of Wall Street's expectations, sending shares lower despite a year that has otherwise rewarded investors handsomely. The Boca Raton-based plasma therapeutics company posted Q1 2025 revenue of $114.80 million, up 40.2% year-over-year but trailing the $116.40 million consensus by 1.37%, while GAAP diluted EPS of $0.11 missed the $0.13 estimate by 15.38%. The shortfall was tied in part to a one-time impact from voluntary product withdrawals; on an adjusted basis, total revenue reached $118.64 million, reflecting roughly 45% year-over-year growth. Gross margin expanded meaningfully to 53.2% from 47.8% a year ago, driven by a richer mix of higher-margin immunoglobulin sales. Offsetting the near-term miss, management raised full-year 2025 revenue guidance to more than $500.00 million and set a 2026 target of $625.00 million or more, with a longer-term pre-2030 annual revenue goal lifted to $1.10 billion, supported by FDA approval of a yield enhancement process expected to boost finished immunoglobulin output by 20% from the same plasma volume.
- Increased sales of ASCENIV driven by increased physician, payer and patient acceptance and utilization
- More favorable mix of higher margin IG sales
- Operational efficiencies resulting in reduction of manufacturing costs
- Lower interest expense due to debt optimization
“The start to 2025 has been a transformational period for ADMA, with the recent U.S. Food and Drug Administration (FDA) approval of our yield enhancement production process, which we believe paves the way for meaningful forward looking revenue growth and margin expansion, ultimately creating durable stockholder value. ADMA delivered outstanding financial and operational results in the first quarter of 2025, with total reported revenues and Adjusted EBITDA growing by 40% and 81% year-over-year, respectively.”
ADMA Biologics CEO, on the earnings call
Forward Guidance & Outlook
ADMA raised FY 2025 total revenue guidance to more than $500 million and FY 2026 to $625 million or more. FY 2025 Adjusted Net Income guidance was reaffirmed at $175 million or more, while FY 2026 Adjusted Net Income was increased to $245 million or more. FY 2025 and 2026 Adjusted EBITDA guidance was increased to more than $235 million and $340 million or more, respectively. Pre-2030 total annual revenue guidance was increased to $1.1 billion or more with anticipated outsized earnings growth from current margin levels. The recently FDA-approved yield enhancement production process is expected to increase finished IG output by 20% from the same starting plasma volume, with benefits excluded from 2025 guidance and conservatively contemplated in 2026 guidance. ASCENIV demand continues to trend to record highs, with the company expecting ASCENIV's total revenue share to expand throughout 2025 and beyond. The company anticipates generating initial proof-of-concept animal data before year-end 2025 for SG-001, which management believes could generate $300-500 million or more in annual revenue if approved.
ADMA YoY Financials
ADMA Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.